U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539688) titled 'Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma' on Feb. 26.
Brief Summary: This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Inert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)
Intervention:
DRUG: CY-219 CA...